Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide and Laser for CSME
NCT00229918Phase 2
Key facts
- Status
- Unknown
- Start
- Sep 2005
- Countries
- 1
- Sponsor
- Edward Hines Jr. VA Hospital
- Modality
- Orthosteric Ligands
- Conditions
- diabetic macular edema (DME)
01
Overview
Phase 2, randomised, open-label trial of triamcinolone acetonide in diabetic macular edema (DME), sponsored by Edward Hines Jr. VA Hospital. Primary endpoint: Moderate vision loss at 2 months. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 25-80 with primary or refractory clinically significant macular edema secondary to diabetic retinopathy, excluding those with glaucoma or steroid-induced intraocular pressure elevation.
04
Endpoints
Primary
Moderate vision loss
Beyond the preview
Go deeper on NCT00229918.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229918.